Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PIK3CA mutation
i
Other names:
PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5290
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
PIK3CA mutation
Colorectal Cancer
PIK3CA mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation
HER2 Negative Breast Cancer
PIK3CA mutation
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
PIK3CA mutation
Breast Cancer
PIK3CA mutation
Breast Cancer
AN2025
Sensitive: B - Late Trials
AN2025
Sensitive
:
B
AN2025
Sensitive: B - Late Trials
AN2025
Sensitive
:
B
PIK3CA mutation
Breast Cancer
PIK3CA mutation
Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
PIK3CA mutation
Triple Negative Breast Cancer
PIK3CA mutation
Triple Negative Breast Cancer
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
PIK3CA mutation
Colorectal Cancer
PIK3CA mutation
Colorectal Cancer
panitumumab
Resistant: B - Late Trials
panitumumab
Resistant
:
B
panitumumab
Resistant: B - Late Trials
panitumumab
Resistant
:
B
PIK3CA mutation
HER2 Positive Breast Cancer
PIK3CA mutation
HER2 Positive Breast Cancer
neratinib
Resistant: B - Late Trials
neratinib
Resistant
:
B
neratinib
Resistant: B - Late Trials
neratinib
Resistant
:
B
PIK3CA mutation
HER2 Positive Breast Cancer
PIK3CA mutation
HER2 Positive Breast Cancer
lapatinib
Resistant: B - Late Trials
lapatinib
Resistant
:
B
lapatinib
Resistant: B - Late Trials
lapatinib
Resistant
:
B
PIK3CA mutation
HER2 Positive Breast Cancer
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab
Resistant: B - Late Trials
trastuzumab
Resistant
:
B
trastuzumab
Resistant: B - Late Trials
trastuzumab
Resistant
:
B
PIK3CA mutation
Colorectal Cancer
PIK3CA mutation
Colorectal Cancer
atezolizumab + cobimetinib
Sensitive: B - Late Trials
atezolizumab + cobimetinib
Sensitive
:
B
atezolizumab + cobimetinib
Sensitive: B - Late Trials
atezolizumab + cobimetinib
Sensitive
:
B
PIK3CA mutation
HER2 Positive Breast Cancer
PIK3CA mutation
HER2 Positive Breast Cancer
everolimus
Sensitive: B - Late Trials
everolimus
Sensitive
:
B
everolimus
Sensitive: B - Late Trials
everolimus
Sensitive
:
B
PIK3CA mutation
Non Small Cell Lung Cancer
PIK3CA mutation
Non Small Cell Lung Cancer
erlotinib
Resistant: B - Late Trials
erlotinib
Resistant
:
B
erlotinib
Resistant: B - Late Trials
erlotinib
Resistant
:
B
PIK3CA mutation
Gastric Cancer
PIK3CA mutation
Gastric Cancer
alpelisib
Sensitive: C2 – Inclusion Criteria
alpelisib
Sensitive
:
C2
alpelisib
Sensitive: C2 – Inclusion Criteria
alpelisib
Sensitive
:
C2
PIK3CA mutation
HER2 Positive Breast Cancer
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab + MEN1611
Sensitive: C2 – Inclusion Criteria
trastuzumab + MEN1611
Sensitive
:
C2
trastuzumab + MEN1611
Sensitive: C2 – Inclusion Criteria
trastuzumab + MEN1611
Sensitive
:
C2
PIK3CA mutation
Uterine Cancer
PIK3CA mutation
Uterine Cancer
copanlisib
Sensitive: C2 – Inclusion Criteria
copanlisib
Sensitive
:
C2
copanlisib
Sensitive: C2 – Inclusion Criteria
copanlisib
Sensitive
:
C2
PIK3CA mutation
HER2 Positive Breast Cancer
PIK3CA mutation
HER2 Positive Breast Cancer
MEN1611
Sensitive: C2 – Inclusion Criteria
MEN1611
Sensitive
:
C2
MEN1611
Sensitive: C2 – Inclusion Criteria
MEN1611
Sensitive
:
C2
PIK3CA mutation
Breast Cancer
PIK3CA mutation
Breast Cancer
palbociclib
Sensitive: C2 – Inclusion Criteria
palbociclib
Sensitive
:
C2
palbociclib
Sensitive: C2 – Inclusion Criteria
palbociclib
Sensitive
:
C2
PIK3CA mutation
Ovarian Cancer
PIK3CA mutation
Ovarian Cancer
CYH33
Sensitive: C2 – Inclusion Criteria
CYH33
Sensitive
:
C2
CYH33
Sensitive: C2 – Inclusion Criteria
CYH33
Sensitive
:
C2
PIK3CA mutation
Breast Cancer
PIK3CA mutation
Breast Cancer
MEN1611
Sensitive: C2 – Inclusion Criteria
MEN1611
Sensitive
:
C2
MEN1611
Sensitive: C2 – Inclusion Criteria
MEN1611
Sensitive
:
C2
PIK3CA mutation
Breast Cancer
PIK3CA mutation
Breast Cancer
GDC-0032
Sensitive: C2 – Inclusion Criteria
GDC-0032
Sensitive
:
C2
GDC-0032
Sensitive: C2 – Inclusion Criteria
GDC-0032
Sensitive
:
C2
PIK3CA mutation
Gastric Cancer
PIK3CA mutation
Gastric Cancer
AZD5363
Sensitive: C2 – Inclusion Criteria
AZD5363
Sensitive
:
C2
AZD5363
Sensitive: C2 – Inclusion Criteria
AZD5363
Sensitive
:
C2
PIK3CA mutation
Squamous Cell Carcinoma of Head and Neck
PIK3CA mutation
Squamous Cell Carcinoma of Head and Neck
alpelisib
Sensitive: C2 – Inclusion Criteria
alpelisib
Sensitive
:
C2
alpelisib
Sensitive: C2 – Inclusion Criteria
alpelisib
Sensitive
:
C2
PIK3CA mutation
Hormone Receptor Positive Breast Cancer
PIK3CA mutation
Hormone Receptor Positive Breast Cancer
alpelisib
Sensitive: C2 – Inclusion Criteria
alpelisib
Sensitive
:
C2
alpelisib
Sensitive: C2 – Inclusion Criteria
alpelisib
Sensitive
:
C2
PIK3CA mutation
Solid Tumor
PIK3CA mutation
Solid Tumor
copanlisib
Sensitive: C2 – Inclusion Criteria
copanlisib
Sensitive
:
C2
copanlisib
Sensitive: C2 – Inclusion Criteria
copanlisib
Sensitive
:
C2
PIK3CA mutation
Non Small Cell Lung Cancer
PIK3CA mutation
Non Small Cell Lung Cancer
U3-1402
Sensitive: C3 – Early Trials
U3-1402
Sensitive
:
C3
U3-1402
Sensitive: C3 – Early Trials
U3-1402
Sensitive
:
C3
PIK3CA mutation
Triple Negative Breast Cancer
PIK3CA mutation
Triple Negative Breast Cancer
everolimus
Sensitive: C3 – Early Trials
everolimus
Sensitive
:
C3
everolimus
Sensitive: C3 – Early Trials
everolimus
Sensitive
:
C3
PIK3CA mutation
Urothelial Cancer
PIK3CA mutation
Urothelial Cancer
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
PIK3CA mutation
Squamous Cell Carcinoma of Head and Neck
PIK3CA mutation
Squamous Cell Carcinoma of Head and Neck
temsirolimus
Sensitive: C3 – Early Trials
temsirolimus
Sensitive
:
C3
temsirolimus
Sensitive: C3 – Early Trials
temsirolimus
Sensitive
:
C3
PIK3CA mutation
Non Small Cell Lung Cancer
PIK3CA mutation
Non Small Cell Lung Cancer
ensartinib
Resistant: C3 – Early Trials
ensartinib
Resistant
:
C3
ensartinib
Resistant: C3 – Early Trials
ensartinib
Resistant
:
C3
PIK3CA mutation
Breast Cancer
PIK3CA mutation
Breast Cancer
bevacizumab
Sensitive: C3 – Early Trials
bevacizumab
Sensitive
:
C3
bevacizumab
Sensitive: C3 – Early Trials
bevacizumab
Sensitive
:
C3
PIK3CA mutation
Breast Cancer
PIK3CA mutation
Breast Cancer
ribociclib
Sensitive: C3 – Early Trials
ribociclib
Sensitive
:
C3
ribociclib
Sensitive: C3 – Early Trials
ribociclib
Sensitive
:
C3
PIK3CA mutation
Hormone Receptor Positive Breast Cancer
PIK3CA mutation
Hormone Receptor Positive Breast Cancer
fulvestrant + anastrozole
Sensitive: C3 – Early Trials
fulvestrant + anastrozole
Sensitive
:
C3
fulvestrant + anastrozole
Sensitive: C3 – Early Trials
fulvestrant + anastrozole
Sensitive
:
C3
PIK3CA mutation
Breast Cancer
PIK3CA mutation
Breast Cancer
CDK6 inhibitor
Resistant: C3 – Early Trials
CDK6 inhibitor
Resistant
:
C3
CDK6 inhibitor
Resistant: C3 – Early Trials
CDK6 inhibitor
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login